Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.48 |
| ▸ | DRD2 | P14416 | 9/20 | 0.48 |
| ▸ | HTR2C | P28335 | 9/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | MPO | P05164 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL31411475 | 0.89 | HTR2A (0.41) | HTR2ADRD2HTR2CMPOPARP1 | |
| SCHEMBL31411334 | 0.87 | TAAR1 (0.44) | HTR2AHTR2CSLC6A4MPOAR | |
| SCHEMBL31411300 | 0.82 | HTR2A (0.43) | HTR2ADRD2HTR2CMPOAR | |
| SCHEMBL13122355 | 0.79 | AR (0.43) | SLC6A4MPOARGPR84PARP1 | |
| Fumaric Acid SCHEMBL31411380 | 0.77 | HTR7 (0.46) | HTR2AHTR2CPARP1 | |
| SCHEMBL31411284 | 0.76 | HTR2A (0.41) | HTR2ADRD2HTR2C | |
| SCHEMBL24243685 | 0.74 | MPO (0.63) | HTR2ADRD2HTR2CSLC6A4MPO | |
| SCHEMBL30053523 | 0.74 | MPO (0.63) | HTR2ADRD2HTR2CSLC6A4MPO | |
| SCHEMBL31411332 | 0.74 | ALDH1A1 (0.36) | HTR2ADRD2HTR2C | |
| SCHEMBL5638323 | 0.74 | AR (0.39) | SLC6A4MPOARGPR84PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885DRD2 226/4885HTR2C 23/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885DRD2 226/4885HTR2C 23/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885DRD2 226/4885HTR2C 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.